Cargando…

Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and all‐cause mortality: Findings from the SMART cohort

AIM: To quantify the magnitude and specific contributions of known cardiovascular risk factors leading to higher cardiovascular risk and all‐cause mortality caused by type 2 diabetes (T2D). METHODS: Mediation analysis was performed to assess the relative contributions of known classical risk factors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharif, Shahnam, Groenwold, Rolf H. H., van der Graaf, Yolanda, Berkelmans, Gijs F. N., Cramer, Maarten J., Visseren, Frank L. J., Westerink, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767388/ https://www.ncbi.nlm.nih.gov/pubmed/31062479 http://dx.doi.org/10.1111/dom.13759

Ejemplares similares

Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes
por: Sharif, Shahnam, et al.
Publicado: (2021)

Arterial stiffness as a risk factor for cardiovascular events and all‐cause mortality in people with Type 2 diabetes
por: Sharif, S., et al.
Publicado: (2019)

The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease
por: Bots, Sophie H., et al.
Publicado: (2016)

Modifiable risk factors in adults with and without prior cardiovascular disease: findings from the Indonesian National Basic Health Research
por: Arsyad, Dian Sidik, et al.
Publicado: (2022)

Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART‐REACH Model
por: Kaasenbrood, Lotte, et al.
Publicado: (2018)

Random measurement error: Why worry? An example of cardiovascular risk factors
por: Brakenhoff, Timo B., et al.
Publicado: (2018)

Screen-detected abnormal ankle brachial index: A risk indicator for future cardiovascular morbidity and mortality in patients with manifest cardiovascular disease
por: Jagt, Vivianne L., et al.
Publicado: (2022)

Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. The SMART study
por: Verhagen, Sandra N, et al.
Publicado: (2011)

Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?
por: Berkelmans, Gijs F. N., et al.
Publicado: (2020)

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials
por: de Jong, Marit, et al.
Publicado: (2017)

Relationship between classic vascular risk factors and cumulative recurrent cardiovascular event burden in patients with clinically manifest vascular disease: results from the UCC-SMART prospective cohort study
por: de Vries, Tamar Irene, et al.
Publicado: (2021)

Added value of cardiovascular calcifications for prediction of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease
por: van ’t Klooster, Cilie C., et al.
Publicado: (2021)

The readiness of public primary health care (PUSKESMAS) for cardiovascular services in Makasar city, Indonesia
por: Arsyad, Dian Sidik, et al.
Publicado: (2022)

The effect of computerized decision support systems on cardiovascular risk factors: a systematic review and meta-analysis
por: Groenhof, T. Katrien J., et al.
Publicado: (2019)

The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study
por: van’t Klooster, Cilie C, et al.
Publicado: (2019)

Prediction of Lifetime and 10-Year Risk of Cancer in Individual Patients With Established Cardiovascular Disease
por: van ’t Klooster, Cilie C., et al.
Publicado: (2020)

Prediction of Cardiovascular Events by Using Non-Vascular Findings on Routine Chest CT
por: de Jong, Pim A., et al.
Publicado: (2011)

Physical exercise volume, type, and intensity and risk of all-cause mortality and cardiovascular events in patients with cardiovascular disease: a mediation analysis
por: Bonekamp, Nadia E, et al.
Publicado: (2023)

Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm
por: Hageman, Steven H J, et al.
Publicado: (2022)

Cohort profile: the Utrecht Cardiovascular Cohort–Second Manifestations of Arterial Disease (UCC-SMART) Study–an ongoing prospective cohort study of patients at high cardiovascular risk in the Netherlands
por: Castelijns, Maria C, et al.
Publicado: (2023)

Impact of a Patient’s Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making
por: de Vries, Tamar I., et al.
Publicado: (2021)

Pharmacological and non-pharmacological interventions to influence adipose tissue function
por: Westerink, Jan, et al.
Publicado: (2011)

Cardiovascular risk factor treatment targets and renal complications in high risk vascular patients: a cohort study
por: Selvarajah, Sharmini, et al.
Publicado: (2011)

Risk Factor Clusters and Cardiovascular Disease in High-Risk Patients: The UCC-SMART Study
por: Holthuis, Emily I., et al.
Publicado: (2021)

Routinely measured hematological parameters and prediction of recurrent vascular events in patients with clinically manifest vascular disease
por: Kofink, Daniel, et al.
Publicado: (2018)

The relation between urinary sodium and potassium excretion and risk of cardiovascular events and mortality in patients with cardiovascular disease
por: Groenland, Eline H., et al.
Publicado: (2022)

β-Blockers and All-Cause Mortality in Adults with Episodes of Acute Bronchitis: An Observational Study
por: Rutten, Frans H., et al.
Publicado: (2013)

Development of a clinical decision tool to reduce diagnostic testing for primary aldosteronism in patients with difficult-to-control hypertension
por: van Kleef, Monique E. A. M., et al.
Publicado: (2020)

Physical Activity and Characteristics of the Carotid Artery Wall in High‐Risk Patients—The SMART (Second Manifestations of Arterial Disease) Study
por: Boss, H. Myrthe, et al.
Publicado: (2017)

Novel Biomarkers to Improve the Prediction of Cardiovascular Event Risk in Type 2 Diabetes Mellitus
por: van der Leeuw, Joep, et al.
Publicado: (2016)

Chronic kidney disease and atrial fibrillation: A dangerous combination
por: Ocak, Gurbey, et al.
Publicado: (2022)

Multifocal cardiovascular calcification in patients with established cardiovascular disease; prevalence, risk factors, and relation with recurrent cardiovascular disease
por: van 't Klooster, Cilie C., et al.
Publicado: (2020)

Major adverse cardiovascular events and all-cause mortality after emergency general surgery among kidney failure patients
por: Anderson, Benjamin, et al.
Publicado: (2022)

The relationship between walking speed and changes in cardiovascular risk factors during a 12-day walking tour to Santiago de Compostela: a cohort study
por: Bemelmans, Remy H H, et al.
Publicado: (2012)

Plasma COOH-Terminal Proendothelin-1: A marker of fatal cardiovascular events, all-cause mortality, and new-onset albuminuria in type 2 diabetes? (ZODIAC-29)
por: Drion, Iefke, et al.
Publicado: (2012)

Impact of diabesity phenotype on cardiovascular diseases, major cardiovascular events and all-cause mortality
por: Mehrabani-Zeinabad, Kamran, et al.
Publicado: (2023)

Serum IL8 is not associated with cardiovascular events but with all-cause mortality
por: Moreno Velásquez, Ilais, et al.
Publicado: (2019)

Association of social relationships with incident cardiovascular events and all-cause mortality
por: Gronewold, Janine, et al.
Publicado: (2020)

End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study
por: Østergaard, Helena Bleken, et al.
Publicado: (2021)

External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease
por: Smidt, Lisanne C. A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2kgpgct61e4mj8t49ekb6s3qvb